1. BRUSSELS – BUDAPEST – FLORENCE – LISBON – MADRID – MILAN – NEW YORK PARIS – PHILADELPHIA – PRAGUE – ROME – SOFIA – VIENNA - VILNIUS www.aimgroupinternational.com New Potential Sponsorship Strategies for Cardiovascular Societies Stefano Remiddi, AIM Group Int.l Strategic Consultant Hungarian Society of Hypertension Siòfok, September 27th, 2014

2. Big Pharma: a new growing period is coming !

3. But… Therapeutic Areas will be different

4. Driven by Big Giants only September 1st, 2014: NOVARTIS announces outstanding study results for LCZ696, a new agent against Hear Failure. NOVARTIS shares rose +5% in the following 3 days (business potential estimated = 6 Bil. $ on annual basis). September 4th, 2014: FDA grants accelerated approval for KEYTRUDA, a new Merck drug against Melanoma, first of a new class of agents (PD-1 Inhibitors). Expected price per Patient = 100.000 USD. For the first six months in 2014, SOVALDI, the new Gilead breakthrough therapy for Hepatitis C, achieved worlwide sales of 5.8 Bil. $ (price per Patient = 30.000 €).

5. Top 10 Pharma Companies in 2013 CompanySales (USD Bill.) R&D Spend (USD MilL.) R&D (%) 1. PFIZER (NY, US)47.4047,04614.9 2. NOVARTIS (Basel, CH) *45.4188,83119.4 3. MERCK (NJ, US)41.1437,91119.2 4. SANOFI (Paris, FR) *38.3706,11715.9 5. ROCHE (Basel, CH)37.5428,03221.4 6. GLAXOSMITHKLINE (UK)33.1075,25515.9 7. ASTRAZENECA (UK)27.0644,45216.4 8. JOHNSON&JOHNSON (NJ, US)23.4915,36222.8 9. ABBOTT (IL, US)23.1192,90012.5 10. ELI LILLY (IN, US)18.5095,07427.4 Source: Pharmaceutical Executive 2013 (*) Companies with new breaktrough CV products in R&D

6. BRUSSELS – BUDAPEST – FLORENCE – LISBON – MADRID – MILAN – NEW YORK PARIS – PHILADELPHIA – PRAGUE – ROME – SOFIA – VIENNA - VILNIUS www.aimgroupinternational.com Key Considerations  Sponsorship opportunities for Pharma Companies at the events of the Cardiovascular Societies are constantly declining  Young Fellows and other Specialists are less represented in the International Congresses  Number of Countries represented at the International Congresses is reducing over time  Pharma Industry Sponsorship will be further reduced because of the lack on new CV (AntiHT) Agents  There is the need to find new avenues preserving the Scientific Core of CV Scientific Societies but trying to expand a little bit the range of activities towards new directions to grow

7. BRUSSELS – BUDAPEST – FLORENCE – LISBON – MADRID – MILAN – NEW YORK PARIS – PHILADELPHIA – PRAGUE – ROME – SOFIA – VIENNA - VILNIUS www.aimgroupinternational.com First Step: Line Extension

8. BRUSSELS – BUDAPEST – FLORENCE – LISBON – MADRID – MILAN – NEW YORK PARIS – PHILADELPHIA – PRAGUE – ROME – SOFIA – VIENNA - VILNIUS www.aimgroupinternational.com Line Extension of Current Key Topics: Medical Devices

9. BRUSSELS – BUDAPEST – FLORENCE – LISBON – MADRID – MILAN – NEW YORK PARIS – PHILADELPHIA – PRAGUE – ROME – SOFIA – VIENNA - VILNIUS www.aimgroupinternational.com Digital Revolution in Health Care is expected to mobilize high investments with a significant shift to Home Care Assistance

10. BRUSSELS – BUDAPEST – FLORENCE – LISBON – MADRID – MILAN – NEW YORK PARIS – PHILADELPHIA – PRAGUE – ROME – SOFIA – VIENNA - VILNIUS www.aimgroupinternational.com Potential Key Digital Players/Sponsor in Europe

11. BRUSSELS – BUDAPEST – FLORENCE – LISBON – MADRID – MILAN – NEW YORK PARIS – PHILADELPHIA – PRAGUE – ROME – SOFIA – VIENNA - VILNIUS www.aimgroupinternational.com Line Extension of Current Key Topics: Diagnostics & Genetics

12. BRUSSELS – BUDAPEST – FLORENCE – LISBON – MADRID – MILAN – NEW YORK PARIS – PHILADELPHIA – PRAGUE – ROME – SOFIA – VIENNA - VILNIUS www.aimgroupinternational.com Line Extension of Current Key Topics: Life Style Changes

13. BRUSSELS – BUDAPEST – FLORENCE – LISBON – MADRID – MILAN – NEW YORK PARIS – PHILADELPHIA – PRAGUE – ROME – SOFIA – VIENNA - VILNIUS www.aimgroupinternational.com Second Step: Technology Integration

14. Web Marketing e Dematerializzazione Web Marketing & Dematerialization

15. Web Marketing: Impact on Physician activity

16. EU Commission: Green Paper on Mobile Health

17. DataN. App disponibiliN. Download 11 Luglio 2008500- 9 Settembre 20083.000100 Milioni 4 Novembre 2009100.0002.5 Miliardi 4 Ottobre 2011500.00018 Miliardi 16 Maggio 2013850.00050 Miliardi APP proposito… ma quante “App” esistono ?... Application for the future

18. Studio Consulenziale Dr. S.Remiddi The new Targets: Patient Communities

19. Web Marketing: Social Media & Gamification

20. Web Site & Web Engagement Visual patterns observed during a web site navigation: performance of the customer engagement related with e-commerce activity “Eye Gaze Patterns while Searching vs. Browsing a Website“ Sav Shrestha e Kelsi Lenz, Usability News,2007Eye Gaze Patterns while Searching vs. Browsing a Website

21. BRUSSELS – BUDAPEST – FLORENCE – LISBON – MADRID – MILAN – NEW YORK PARIS – PHILADELPHIA – PRAGUE – ROME – SOFIA – VIENNA - VILNIUS www.aimgroupinternational.com Third Step: Range Expansion

22. BRUSSELS – BUDAPEST – FLORENCE – LISBON – MADRID – MILAN – NEW YORK PARIS – PHILADELPHIA – PRAGUE – ROME – SOFIA – VIENNA - VILNIUS www.aimgroupinternational.com Expansion of Current Horizon High Blood PressureOrgan DamagePrevention Interest

23. BRUSSELS – BUDAPEST – FLORENCE – LISBON – MADRID – MILAN – NEW YORK PARIS – PHILADELPHIA – PRAGUE – ROME – SOFIA – VIENNA - VILNIUS www.aimgroupinternational.com Expansion of Current Horizon: Prevention  Life Style Changes  Food  Diet  Ionic-Metabolic Balance  Nutraceuticals  Sports & Wellness  QoL  HT Prevention Guidelines

24. BRUSSELS – BUDAPEST – FLORENCE – LISBON – MADRID – MILAN – NEW YORK PARIS – PHILADELPHIA – PRAGUE – ROME – SOFIA – VIENNA - VILNIUS www.aimgroupinternational.com Nutraceuticals

25. BRUSSELS – BUDAPEST – FLORENCE – LISBON – MADRID – MILAN – NEW YORK PARIS – PHILADELPHIA – PRAGUE – ROME – SOFIA – VIENNA - VILNIUS www.aimgroupinternational.com Conclusions & Suggested Actions  Develop a platform Strategy to sinergy the Technology Integration and remain highly attractive for potential Sponsors in this new area  Design Web Site, Web Marketing Activities and Integrate all Communication Channels including Social Network Strategy for Patient Communities  Be ready to create the necessary spaces at each Congress (scientific arena & commercial/sponsorship arena)  Interact with other key stakeholders in the new areas (eg European Association of Nutraceuticals, Sports & Medicine, Dietology Associations)

26. Thanks for your attention !